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and 49% were male. Users with a VTE history (12%) had a longer duration of anti-
coagulant use versus those without a VTE history. Of those with a VTE history,
15% used anticoagulants for2 months. The average/median duration of therapy
was 15/2, 2.3/2, 19/12, 41/30 days for all users, users of unfractionated heparin
(UFH), low-molecular-weight heparin (LMWH), and vitamin K antagonist (VKA),
respectively. Anticoagulant use was highest in colorectal cancer patients (40%) and
lowest in bladder cancer patients (9%). Most commonly prescribed anticoagulants
were UFH (75%), VKA (20%), and LMWH (8%). CONCLUSIONS: Approximately 1/3 of
cancer patients used anticoagulants around chemotherapy. Anticoagulant use var-
ies by tumor type ranging between 9%-40%. Heparin was the most commonly
prescribed agent and VKA had the longest therapy duration.
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OBJECTIVES: To compare the potential cost of long-acting treatments with lan-
reotide vs octreotide for GEP-NET using patient treatment characteristics from the
PHARMO Record Linkage System (RLS) in the Netherlands. METHODS: A cost min-
imization model was used to compare lifetime costs of the SSAs. Data for patients
receiving outpatient dispensing of long-acting SSA (2003–2010) were selected from
PHARMO RLS. GEP-NET patients were identified by relevant hospital discharge
diagnoses. Dosing and injection intervals were assessed during the first stable
treatment period (i.e., the period of SSA dispensings with constant dosage and little
variation in injection intervals). RESULTS: A total of 82 octreotide LAR users and 10
lanreotide Autogel users were identified. Stable treatment was observed in 54/82
(66%) octreotide and 8/10 (80%) lanreotide users; median (IQR) duration of the first
stable phase was 3 (2-6) and 5 (4-6) months, respectively. Among stable users, most
received medium doses (5/8 (63%) vs 35/54 (65%)). One (2%) octreotide user and
none of the lanreotide users received low dose. High doses were received by 18/54
(33%) on octreotide vs 3/8 (38%) on lanreotide. Stratified by week, 9/54 (17%) oc-
treotide users received injections every 3 weeks or more frequently, 36/54 (67%)
every 4 weeks, 7/54 (13%) every 5 weeks and 2/54 (3%) every 6 weeks or less fre-
quently; 7/8 (88%) lanreotide users received injections every 4 weeks and 1/54 (13%)
every 6 weeks or less frequently. Mean injection intervals were 278 days for
octreotide and 3110 days for lanreotide. This resulted in an average GEP-NET
patient cost 7% less with lanreotide than octreotide based on the cost minimization
model. CONCLUSIONS: This analysis suggests long-acting lanreotide use may re-
duce costs compared with long-acting octreotide. The driver of cost savings was
the longer injection interval with lanreotide during stable treatment for GEP-NET.
The nature of the disease implies low patient numbers.
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There is limited data available on health care resource utilization (HRU) associated
with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVES: To as-
sess HRU in mCRPC patients during treatment. METHODS: Observational, retro-
spective, year-long study conducted in 47 centres specialised in prostate cancer
(PC) in 6 countries: Belgium, France, Germany, Sweden, the Netherlands, and the
UK. Patients with confirmed mCRPC diagnosis and documented disease progres-
sion were eligible. HRU data over the previous 2 years (or from mCRPC diagnosis
onwards if 2 years) were collected from patients’ medical records by physicians.
Interim results on 212 patients, of 699 included patients, are presented below.
RESULTS: Mean age was 73.0 years. Mean time since PC diagnosis was 6.6 years. At
diagnosis, 35.7% of patients had metastases and 79.7% had Gleason score 7. At
inclusion, 33.8% of patients had never been treated with any prior chemotherapy,
35.3% had been treated with chemotherapy previously and 30.8% were currently
undergoing chemotherapy. Mean time since failure on androgen-deprivation ther-
apy was respectively 1.2, 1.6 and 1.5 years. Chemotherapy consisted principally of
docetaxel (82.0%). Patients without prior chemotherapy presented lower rates of PC
surgery (5.9%) than patients with past (11.3%) or ongoing chemotherapy (12.9%).
Palliative radiotherapy was more frequent in patients with past chemotherapy
(28.2%) than in patients without prior chemotherapy (19.1%) or with ongoing che-
motherapy (14.5%). Higher hospitalisation rates were observed in patients with
past (43.7%) or ongoing chemotherapy (43.5%) than in patients without prior che-
motherapy (23.5%). Mean hospitalisation durations were roughly equivalent (re-
spectively 6.1, 6.8 and 5.7 days). Emergency room visits were more frequent in
patients with ongoing chemotherapy (14.5%) than in patients without prior che-
motherapy (7.4%) or with past chemotherapy (9.9%). CONCLUSIONS: This study
provides HRU information, which will be implemented into a cost analysis in order
to highlight the determinants of the economic burden of mCRPC patients.
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OBJECTIVES: Chemotherapy-induced FN can result in reduced chemotherapy de-
livery, unplanned hospitalizations, increased mortality risk, and substantial HCU.
Little is known about FN-related HCU among cancer patients in Dutch clinical
practice. METHODS: Data from incident adult BC and NHL-patients from 1998–
2007 were obtained from the PHARMO Record Linkage System, including phar-
macy, hospital, and lab data. Eligible patients had12 months medical history and
received chemotherapy within 6 months after cancer diagnosis. Patients develop-
ing FN within 6 months after first chemotherapy (“FN-patients”) were matched 1:2
on gender, birth-year, and chemotherapy-regimen to patients without FN (“non-
FN-patients”). HCU-data (hospitalizations, medical procedures, drug use [number
dispensed]) was tallied from entry date (date of FN or matched date for non-FN-
patients) for up to 3 months. Statistics are descriptive with crude odds ratios (OR).
RESULTS: As a result, 80/1033 (8%) BC-patients developed FN. 95/486 (20%) NHL-
patients developed FN. Eighty and 89 FN-patients were matched, respectively.
More FN-patients than non-FN-patients were hospitalized in the first month after
entry date (BC: 73% vs 14% [OR23.0; 95%CI:(8.3-63.7)]; NHL: 78% vs 33% [OR7.6;
95%CI:(3.9-15.1)]). These differences were mainly due to FN-related hospitaliza-
tions (BC: 55% vs 1%; NHL: 47% vs 4%). FN-patients also had a longer mean length of
stay per all-cause hospitalization (BC: 4.6 vs 1.9 days; NHL: 10.1 vs 3.0 days). Mean
number of total drugs dispensed in the first month was higher in FN-patients than
in non-FN-patients (BC: 5.8 vs 3.1; NHL: 8.5 vs 3.6), as was use of anti-infectious
agents (BC: 99% vs 11%; NHL: 96% vs 20%) and other non-chemotherapy drugs. More
FN-patients than non-FN-patients had medical procedures (BC: 14% vs 3%; NHL:
13% vs 8%). HCU-differences between FN-patients and non-FN-patients were
maintained after 3 months. CONCLUSIONS: HCU in BC and NHL-patients with FN
in the Netherlands is substantial. Reduction of FN may improve quality of life and
save resources.
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OBJECTIVES: There has been concern that new oncology medicines may not be
accessible to patients due to the requirement to demonstrate cost-effectiveness in
order to gain public reimbursement. In Australia, Public Summary Documents
(PSDs) reporting on the Pharmaceutical Benefits Advisory Committee’s (PBAC) de-
cision making relating to government reimbursement of medicines have been pub-
lished since July 2005. A review of PSDs reporting on oncology drugs which pre-
sented cost-effectiveness analyses was undertaken to identify the success factors
for achieving a positive recommendation. METHODS: Data related to history, clin-
ical outcomes, cost-effectiveness and recommendations for oncology drugs from
published PSDs between July 2005 and November 2011 were extracted and
reviewed. RESULTS: Eighty-one PSDs were reviewed of which 51 were first, 18
second and 12 subsequent submissions. The PBAC recommended 26 for listing on
the Australian Pharmaceutical Benefits Scheme (PBS). Of the first, second and sub-
sequent submissions, 29%, 33% and 42% received a positive recommendation re-
spectively. Of those that reported a AU$/QALY, the range was: below $15k; 0% of
instances, 15-45k; 67%, 45-75k; 33%, 75-105k; 0% and above 105k; 0%. The findings
were generally similar when AU$/LYG was reported, however one product was
approved with AU$/LYG greater than $105k under the “rule of rescue”. Of the prod-
ucts approved with AU$/QALY or LYG greater than $45k factors that were noted
included high clinical need, risk sharing agreement and further price negotiation.
CONCLUSIONS:Cost per QALY above $45k is acceptable in conjunction with factors
such as clinical need and robust evidence. Nevertheless, further price negotiation
may be required to gain reimbursement on the Australian PBS.
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OBJECTIVES: The NICE reference case requires that health-related quality of life
(HRQoL) data should be reported directly from patients, preferably using the EQ-5D
(2008 Methods guide, updating recommendations in 2004 Methods guide). The ob-
jective of this review was to evaluate the source of utility data in oncology apprais-
als conducted since the 2004 Methods guide up to the present day. METHODS:
Completed NICE appraisals of oncology drugs conducted since the 2004 methods
guide were reviewed. Data including model structure, utility data sources, and
values reported for the main health states were extracted. RESULTS: Fifty-one
completed NICE appraisals were reviewed. This included 61 separate evaluations
accounting for MTAs. 43% provided utilities based on EQ-5D data from patients
with the relevant disease for at least one of the main health states in the model.
However, there was considerable variation within this – only 34% included EQ-5D
data for all main health states, and in only 28% were utilities precisely matched to
the indication sought (same therapy line etc. . .). Only 20% included EQ-5D data
from patients actually receiving the drug being appraised. In total, 28% of submis-
sions provided data from patients on the drug under consideration (either through
EQ-5D or another measure). Although most appraisals were for advanced/meta-
static cancer, utility values reported were reasonably high - the majority of apprais-
als reported utilities for the initial health state (typically stable disease) of between
0.65 – 0.85. CONCLUSIONS: This review highlights the paucity of available utility
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